In vivo reprogramming of cancer metabolism by MYC

Frontiers in Cell and Developmental Biology

Volumn 5, Issue APR, 2017, Pages

  Camarda, Roman ^a   Williams, Jeremy ^a   Goga, Andrei ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fatty acid oxidation; Glucose; Glutamine; Metabolism; MYC; Ras proteins; Therapeutic irrigation; Transgenic cancer models

Indexed keywords

EID: 85026459103     PISSN: None     EISSN: 2296634X     Source Type: Journal    
DOI: 10.3389/fcell.2017.00036     Document Type: Review

References (99)

1. Abbondante, S., Eckel-Mahan, K. L., Ceglia, N. J., Baldi, P., and Sassone-Corsi, P. (2016). Comparative circadian metabolomics reveal differential effects of nutritional challenge in the Serum and Liver. J. Biol. Chem. 291, 2812-2828. doi: 10.1074/jbc. M115.681130
2. Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A., and Wakil, S. J. (2001). Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616. doi: 10.1126/science.1056843
3. Allen, T. D., Zhu, C. Q., Jones, K. D., Yanagawa, N., Tsao, M. S., and Bishop, J. M. (2011). Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer Res. 71, 2212-2221. doi: 10.1158/0008-5472.CAN-10-3590
4. Altman, B. J., Hsieh, A. L., Sengupta, A., Krishnanaiah, S. Y., Stine, Z. E., Walton, Z. E., et al. (2015). MYC disrupts the circadian clock and metabolism in cancer cells. Cell Metab. 22, 1009-1019. doi: 10.1016/j.cmet.2015.09.003
5. Altman, B. J., Stine, Z. E., and Dang, C. V. (2016). From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619-634. doi: 10.1038/nrc.2016.71
6. Anderton, B., Camarda, R., Balakrishnan, S., Balakrishnan, A., Kohnz, R. A., Lim, L., et al. (2017). MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. EMBO Rep. doi: 10.15252/embr.201643068. Available online at: http://embor.embopress.org/content/early/2017/02/20/embr.201643068.long
7. Aran, D., Sirota, M., and Butte, A. J. (2015). Systematic pan-cancer analysis of tumour purity. Nat. Commun. 6, 8971. doi: 10.1038/ncomms9971
8. Barna, M., Pusic, A., Zollo, O., Costa, M., Kondrashov, N., Rego, E., et al. (2008). Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456, 971-975. doi: 10.1038/nature07449
9. Beharry, Z., Mahajan, S., Zemskova, M., Lin, Y.-W., Tholanikunnel, B. G., Xia, Z., et al. (2011). The Pim protein kinases regulate energy metabolism and cell growth. Proc. Natl. Acad. Sci. U.S.A. 108, 528-533. doi: 10.1073/pnas.1013214108
10. Bott, A. J., Peng, I. C., Fan, Y., Faubert, B., Zhao, L., Li, J., et al. (2015). Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 22, 1068-1077. doi: 10.1016/j.cmet.2015.09.025
11. Brasó-Maristany, F., Filosto, S., Catchpole, S., Marlow, R., Quist, J., Francesch-Domenech, E., et al. (2016). PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat. Med. 22, 1303-1313. doi: 10.1038/nm.4198
12. Buescher, J. M., Antoniewicz, M. R., Boros, L. G., Burgess, S. C., Brunengraber, H., Clish, C. B., et al. (2015). A roadmap for interpreting 13C metabolite labeling patterns from cells. Curr. Opin. Biotechnol. 34, 189-201. doi: 10.1016/j.copbio.2015.02.003
13. Burén, S., Gomes, A. L., Teijeiro, A., Fawal, M.-A., Yilmaz, M., Tummala, K. S., et al. (2016). Regulation of OGT by URI in response to glucose confers c-MYC-dependent survival mechanisms. Cancer Cell 30, 290-307. doi: 10.1016/j.ccell.2016.06.023
14. Cairns, R. A., and Mak, T. W. (2016). The current state of cancer metabolism. Nat. Rev. Cancer 16, 613-614. doi: 10.1038/nrc.2016.100
15. Cairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., et al. (2008). Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14, 471-484. doi: 10.1016/j.ccr.2008.11.002
16. Calvisi, D. F., and Thorgeirsson, S. S. (2005). Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol. Pathol. 33, 181-184. doi: 10.1080/01926230590522095
17. Camarda, R., Zhou, A. Y., Kohnz, R. A., Balakrishnan, S., Mahieu, C., Anderton, B., et al. (2016). Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med. 22, 427-432. doi: 10.1038/nm.4055
18. Cao, M. D., Lamichhane, S., Lundgren, S., Bofin, A., Fjøsne, H., Giskeødegård, G. F., et al. (2014). Metabolic characterization of triple negative breast cancer. BMC Cancer 14:941. doi: 10.1186/1471-2407-14-941
19. Cao, Z., Fan-Minogue, H., Bellovin, D. I., Yevtodiyenko, A., Arzeno, J., Yang, Q., et al. (2011). MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res. 71, 2286-2297. doi: 10.1158/0008-5472.CAN-10-3367
20. Carter, D. R., Sutton, S. K., Pajic, M., Murray, J., Sekyere, E. O., Fletcher, J., et al. (2016). Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis. Mol. Oncol. 10, 866-878. doi: 10.1016/j.molonc.2016.02.004
21. Chang, C. H., Qiu, J., O'Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., et al. (2015). Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229-1241. doi: 10.1016/j.cell.2015.08.016
22. Chou, T. Y., Hart, G. W., and Dang, C. V. (1995). c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J. Biol. Chem. 270, 18961-18965
23. Ciribilli, Y., Singh, P., Inga, A., and Borlak, J. (2016). c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma. Oncotarget 7, 65514-65539. doi: 10.18632/oncotarget.11804
24. Comerford, S. A., Huang, Z., Du, X., Wang, Y., Cai, L., Witkiewicz, A. K., et al. (2014). Acetate dependence of tumors. Cell 159, 1591-1602. doi: 10.1016/j.cell.2014.11.020
25. Cui, M., Wang, Q., and Chen, G. (2016). Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients. Biomed. Chromatogr. 30, 42-47. doi: 10.1002/bmc.3556
26. Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M., and Ruggero, D. (2014). Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157, 1088-1103. doi: 10.1016/j.cell.2014.03.052
27. Dang, C. V. (2011). Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb. Symp. Quant. Biol. 76, 369-374. doi: 10.1101/sqb.2011.76.011296
28. Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., et al. (2016). Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab. 23, 517-528. doi: 10.1016/j.cmet.2016.01.007
29. D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., et al. (2001). c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7, 235-239. doi: 10.1038/84691
30. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., and Thompson, C. B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20. doi: 10.1016/j.cmet.2007.10.002
31. DeRose, Y. S., Wang, G., Lin, Y., Bernard, P. S., Buys, S. S., Ebbert, M. T., et al. (2011). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514-1520. doi: 10.1038/nm.2454
32. Dupuy, F., Tabariès, S., Andrzejewski, S., Dong, Z., Blagih, J., Annis, M. G., et al. (2015). PDK1-dependent metabolic reprogramming dictates metastatic potential in breast cancer. Cell Metab. 22, 577-589. doi: 10.1016/j.cmet.2015.08.007
33. Eberlin, L. S., Gabay, M., Fan, A. C., Gouw, A. M., Tibshirani, R. J., Felsher, D. W., et al. (2014). Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc. Natl. Acad. Sci. U.S.A. 111, 10450-10455. doi: 10.1073/pnas.1409778111
34. Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., et al. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238. doi: 10.1016/S1535-6108(03)00197-1
35. Felsher, D. W., and Bishop, J. M. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207. doi: 10.1016/S1097-2765(00)80367-6
36. Fletcher, J. W., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., et al. (2008). Recommendations on the use of 18F-FDG PET in oncology. J. Nucl. Med. 49, 480-508. doi: 10.2967/jnumed.107.047787
37. Galluzzi, L., Kepp, O., Vander Heiden, M. G., and Kroemer, G. (2013). Metabolic targets for cancer therapy. Nat. Rev. Drug Discov. 12, 829-846. doi: 10.1038/nrd4145
38. Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., et al. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765. doi: 10.1038/nature07823
39. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
40. Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L., and Adams, J. M. (1988). The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167, 353-371
41. Hart, L. S., Cunningham, J. T., Datta, T., Dey, S., Tameire, F., Lehman, S. L., et al. (2012). ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Invest. 122, 4621-4634. doi: 10.1172/JCI62973
42. Hay, N. (2016). Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat. Rev. Cancer 16, 1-15. doi: 10.1038/nrc.2016.77
43. Hofmann, J. W., Zhao, X., De Cecco, M., Peterson, A. L., Pagliaroli, L., Manivannan, J., et al. (2015). Reduced expression of MYC increases longevity and enhances healthspan. Cell 160, 477-488. doi: 10.1016/j.cell.2014.12.016
44. Horiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S., et al. (2016). PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat. Med. 22, 1321-1329. doi: 10.1038/nm.4213
45. Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., et al. (2012). MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679-696. doi: 10.1084/jem.20111512
46. Hu, H., Juvekar, A., Lyssiotis, C. A., Lien, E. C., Albeck, J. G., Oh, D., et al. (2016). Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 164, 433-446. doi: 10.1016/j.cell.2015.12.042
47. Hu, S., Balakrishnan, A., Bok, R. A., Anderton, B., Larson, P. E., Nelson, S. J., et al. (2011). 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab. 14, 131-142. doi: 10.1016/j.cmet.2011.04.012
48. Huang, Q., Tan, Y., Yin, P., Ye, G., Gao, P., Lu, X., et al. (2013). Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 73, 4992-5002. doi: 10.1158/0008-5472.CAN-13-0308
49. Intlekofer, A. M., DeMatteo, R. G., Venneti, S., Finley, L. W., Lu, C., Judkins, A. R., et al. (2015). Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metab. 22, 304-311. doi: 10.1016/j.cmet.2015.06.023
50. Kanaan, Y. M., Sampey, B. P., Beyene, D., Esnakula, A. K., Naab, T. J., Ricks-Santi, L. J., et al. (2014). Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteomics 11, 279-294
51. Kaposi-Novak, P., Libbrecht, L., Woo, H. G., Lee, Y. H., Sears, N. C., Conner, E. A., et al. (2009). Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 69, 2775-2782. doi: 10.1158/0008-5472.CAN-08-3357
52. Kim, J. W., Gao, P., Liu, Y.-C., Semenza, G. L., and Dang, C. V. (2007). Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381-7393. doi: 10.1128/MCB.00440-07
53. Koboldt, D. C., Fulton, R. S., McLellan, M. D., Schmidt, H., Kalicki-Veizer, J., McMichael, J. F., et al. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70. doi: 10.1038/nature11412
54. Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017. doi: 10.1016/j.cell.2009.04.021
55. Kress, T. R., Sabò, A., and Amati, B. (2015). MYC: connecting selective transcriptional control to global RNA production. Nat. Rev. Cancer 15, 593-607. doi: 10.1038/nrc3984
56. Kurhanewicz, J., Vigneron, D. B., Brindle, K., Chekmenev, E. Y., Comment, A., Cunningham, C. H., et al. (2011). Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 13, 81-97. doi: 10.1593/neo.101102
57. Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., et al. (2015). Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131-135. doi: 10.1038/nature15260
58. Le, X., Antony, R., Razavi, P., Treacy, D. J., Luo, F., Ghandi, M., et al. (2016). Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discov. 6, 1134-1147. doi: 10.1158/2159-8290.CD-16-0305
59. LeBleu, V. S., O'Connell, J. T., Gonzalez Herrera, K. N., Wikman, H., Pantel, K., Haigis, M. C., et al. (2014). PGC-1a mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992-1003, 1-15. doi: 10.1038/ncb3039
60. Li, F., Wang, Y., Zeller, K. I., Potter, J. J., Wonsey, D. R., O'Donnell, K., et al. (2005). Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225-6234. doi: 10.1128/MCB.25.14.6225-6234.2005
61. Lieberman, B. P., Ploessl, K., Wang, L., Qu, W., Zha, Z., Wise, D. R., et al. (2011). PET imaging of glutaminolysis in tumors by 18F-(2S, 4R)4-fluoroglutamine. J. Nucl. Med. 52, 1947-1955. doi: 10.2967/jnumed.111.093815
62. Lim, L., Balakrishnan, A., Huskey, N., Jones, K. D., Jodari, M., Ng, R., et al. (2014). MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 59, 202-215. doi: 10.1002/hep.26662
63. Liu, R. Z., Graham, K., Glubrecht, D. D., Germain, D. R., Mackey, J. R., and Godbout, R. (2011). Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am. J. Pathol. 178, 997-1008. doi: 10.1016/j.ajpath.2010.11.075
64. Liu, Y., Hong, Z., Tan, G., Dong, X., Yang, G., Zhao, L., et al. (2014). NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Int. J. Cancer 135, 658-668. doi: 10.1002/ijc.28706
65. Lockwood, W. W., Zejnullahu, K., Bradner, J. E., and Varmus, H. (2012). Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc. Natl. Acad. Sci. U.S.A. 109, 19408-19413. doi: 10.1073/pnas.1216363109
66. Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., et al. (2003). Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. U.S.A. 100, 7841-7846. doi: 10.1073/pnas.1232229100
67. Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K. J., Singh, D. K., Sirasanagandla, S., et al. (2014). Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159, 1603-1614. doi: 10.1016/j.cell.2014.11.025
68. Mayers, J. R., and Vander Heiden, M. G. (2015). Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem. Sci. 40, 130-140. doi: 10.1016/j.tibs.2015.01.004
69. McKeown, M. R., and Bradner, J. E. (2014). Therapeutic strategies to inhibit MYC. Cold Spring Harb. Perspect. Med. 4:a014266. doi: 10.1101/cshperspect.a014266
70. Medina-Cleghorn, D., and Nomura, D. K. (2014). Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms. Chem. Biol. 21, 1171-1184. doi: 10.1016/j.chembiol.2014.07.007
71. Meyer, N., and Penn, L. Z. (2008). Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990. doi: 10.1038/nrc2231
72. Nelson, S. J., Kurhanewicz, J., Vigneron, D. B., Larson, P. E. Z., Harzstark, A. L., Ferrone, M., et al. (2013). Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci. Transl. Med. 5, 198ra108. doi: 10.1126/scitranslmed.3006070
73. Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., et al. (2011). Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503. doi: 10.1038/nm.2492
74. Oldham, W. M., Clish, C. B., Yang, Y., and Loscalzo, J. (2015). Hypoxia-mediated increases in l-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab. 22, 291-303. doi: 10.1016/j.cmet.2015.06.021
75. Pacilli, A., Calienni, M., Margarucci, S., D'Apolito, M., Petillo, O., Rocchi, L., et al. (2013). Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J. Natl. Cancer Inst. 105, 489-498. doi: 10.1093/jnci/djt030
76. Palaskas, N., Larson, S. M., Schultz, N., Komisopoulou, E., Wong, J., Rohle, D., et al. (2011). 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 71, 5164-5174. doi: 10.1158/0008-5472.CAN-10-4633
77. Park, J. H., Vithayathil, S., Kumar, S., Sung, P.-L., Dobrolecki, L. E., Putluri, V., et al. (2016). Fatty acid oxidation-driven Src links mitochondrial energy reprogramming and oncogenic properties in triple-negative breast cancer. Cell Rep. 14, 2154-2165. doi: 10.1016/j.celrep.2016.02.004
78. Pascual, G., Avgustinova, A., Mejetta, S., Martín, M., Castellanos, A., Attolini, C. S.-O., et al. (2016). Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541, 41-45. doi: 10.1038/nature20791
79. Perry, R. H., Bellovin, D. I., Shroff, E. H., Ismail, A. I., Zabuawala, T., Felsher, D. W., et al. (2013). Characterization of MYC-induced tumorigenesis by in situ lipid profiling. Anal. Chem. 85, 4259-4262. doi: 10.1021/ac400479j
80. Pfefferle, A. D., Herschkowitz, J. I., Usary, J., Harrell, J. C., Spike, B. T., Adams, J. R., et al. (2013). Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 14:R125. doi: 10.1186/gb-2013-14-11-r125
81. Priolo, C., Pyne, S., Rose, J., Regan, E. R., Zadra, G., Photopoulos, C., et al. (2014). AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 74, 7198-7204. doi: 10.1158/0008-5472.CAN-14-1490
82. Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S., et al. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431, 1112-1117. doi: 10.1038/nature03043
83. Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S., Goldstein, M. J., et al. (2007). Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110, 2674-2684. doi: 10.1182/blood-2006-09-048033
84. Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., Jungmann, R. A., et al. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. U.S.A. 94, 6658-6663. doi: 10.1073/pnas.94.13.6658
85. Shroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., et al. (2015). MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc. Natl. Acad. Sci. U.S.A. 112, 6539-6544. doi: 10.1073/pnas.1507228112
86. Sloan, E. J., and Ayer, D. E. (2010). Myc, mondo, and metabolism. Genes Cancer 1, 587-596. doi: 10.1177/1947601910377489
87. Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., and Dang, C. V. (2015). MYC, metabolism, and cancer. Cancer Discov. 5, 1024-1039. doi: 10.1158/2159-8290.CD-15-0507
88. Terunuma, A., Putluri, N., Mishra, P., Mathé, E. A., Dorsey, T. H., Yi, M., et al. (2014). MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Invest. 124, 398-412. doi: 10.1172/JCI71180
89. Tward, A. D., Jones, K. D., Yant, S., Kay, M. A., Wang, R., and Bishop, J. M. (2005). Genomic progression in mouse models for liver tumors. Cold Spring Harb. Symp. Quant. Biol. 70, 217-224. doi: 10.1101/sqb.2005.70.058
90. Vander Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033. doi: 10.1126/science.1160809
91. Wahlström, T., and Henriksson, M. A. (2015). Impact of MYC in regulation of tumor cell metabolism. Biochim. Biophys. Acta. 1849, 563-569. doi: 10.1016/j.bbagrm.2014.07.004
92. Wang, H., Lu, J., Edmunds, L. R., Kulkarni, S., Dolezal, J., Tao, J., et al. (2016). Coordinated activities of multiple Myc-dependent and Myc-independent biosynthetic pathways in hepatoblastoma. J. Biol. Chem. 291, 26241-26251. doi: 10.1074/jbc.m116.754218
93. Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., and Bishop, J. M. (2001). Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023-1034. doi: 10.1083/jcb.153.5.1023
94. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G., and Bishop, J. M. (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995. doi: 10.1093/emboj/16.11.2985
95. Wettersten, H. I., Hakimi, A. A., Morin, D., Bianchi, C., Johnstone, M. E., Donohoe, D. R., et al. (2015). Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 75, 2541-2552. doi: 10.1158/0008-5472.CAN-14-1703
96. Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O'Connor, R. S., Altman, B. J., et al. (2015). Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J. Clin. Invest. 125, 2293-2306. doi: 10.1172/JCI75836
97. Yuneva, M. O., Fan, T. W., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., et al. (2012). The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15, 157-170. doi: 10.1016/j.cmet.2011.12.015
98. Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., and Lazebnik, Y. (2007). Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178, 93-105. doi: 10.1083/jcb.200703099
99. Zirath, H., Frenzel, A., Oliynyk, G., Segerström, L., Westermark, U. K., Larsson, K., et al. (2013). MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 110, 10258-10263. doi: 10.1073/pnas.1222404110